Carcinoma In Situ Clinical Trials

52 recruitingLast updated: June 17, 2026

There are 52 actively recruiting carcinoma in situ clinical trials across 27 countries. Studies span Phase 2, Not Applicable, Phase 1, Phase 3, Phase 4. Top locations include Philadelphia, Pennsylvania, United States, Los Angeles, California, United States, Houston, Texas, United States. Updated daily from ClinicalTrials.gov.


Carcinoma In Situ Trials at a Glance

52 actively recruiting trials for carcinoma in situ are listed on ClinicalTrialsFinder across 6 cities in 27 countries. The largest study group is Phase 2 with 16 trials, with the heaviest enrollment activity in Philadelphia, Los Angeles, and Houston. Lead sponsors running carcinoma in situ studies include Thomas Jefferson University, National Cancer Institute (NCI), and Mayo Clinic.

Browse carcinoma in situ trials by phase

Treatments under study

About Carcinoma In Situ Clinical Trials

Looking for clinical trials for Carcinoma In Situ? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Carcinoma In Situ trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Carcinoma In Situ clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 52 trials

Recruiting

Impact of Dietary Inflammatory Potential on Breast Cancer Risk

Breast CarcinomaBreast Atypical Ductal HyperplasiaBreast Atypical Lobular Hyperplasia+2 more
Ohio State University Comprehensive Cancer Center960 enrolled1 locationNCT05178498
Recruiting
Not Applicable

A Novel Fluorescent Ductal Needle for Localization and Sampling of Micro Lesions in Breast Ducts

Mammary TumorNipple DischargeBreast Ductal Carcinoma in Situ
The Fourth Affiliated Hospital of China Medical University300 enrolled1 locationNCT07339306
Recruiting
Phase 2

Evaluation of Novel Iron-based Lymphatic Mapping Agent, Magtrace, for Delayed Sentinel Lymph Node Biopsy (SLNB) in Ductal Carcinoma In-Situ (DCIS)

Ductal Carcinoma in Situ
University of Florida30 enrolled1 locationNCT06868238
Recruiting
Phase 2

A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)

Urinary Bladder NeoplasmsCarcinoma In SituNon-Muscle Invasive Bladder Neoplasms
Merck Sharp & Dohme LLC308 enrolled89 locationsNCT06833073
Recruiting
Phase 3

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Ferring Pharmaceuticals250 enrolled74 locationsNCT06545955
Recruiting
Phase 2

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

Ductal Carcinoma in Situ
QuantumLeap Healthcare Collaborative400 enrolled28 locationsNCT06075953
Recruiting
Phase 3

Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)

Bladder Carcinoma in Situ (CIS)
Fidia Farmaceutici s.p.a.112 enrolled47 locationsNCT05024773
Recruiting
Phase 2

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

Breast CarcinomaBreast Ductal Carcinoma in SituBreast Atypical Hyperplasia+1 more
National Cancer Institute (NCI)66 enrolled3 locationsNCT06195306
Recruiting

Rate of Malignant Transformation and Clinical Characteristics Among an Oral Lichen Planus Cohort: a Retrospective Center Experience

Oral Lichen PlanusOral CarcinomaOral Carcinoma in Situ
Catholic University of the Sacred Heart300 enrolled1 locationNCT06934863
Recruiting
Phase 2

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

Breast CarcinomaEstrogen Receptor-Positive Breast CarcinomaBreast Ductal Carcinoma in Situ+3 more
National Cancer Institute (NCI)200 enrolled11 locationsNCT06184750
Recruiting
Phase 2

Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

Breast CarcinomaBreast Ductal Carcinoma in SituBreast Atypical Hyperplasia+1 more
National Cancer Institute (NCI)80 enrolled4 locationsNCT05941520
Recruiting

Project: Every Child for Younger Patients With Cancer

Malignant Solid NeoplasmNeuroendocrine NeoplasmCentral Nervous System Neoplasm+15 more
Children's Oncology Group75,000 enrolled278 locationsNCT02402244
Recruiting
Phase 1Phase 2

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Non-muscle Invasive Bladder Cancer With Carcinoma in SituSuperficial Bladder Cancer
enGene, Inc.350 enrolled101 locationsNCT04752722
Recruiting

Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery

Invasive Breast CarcinomaBreast Ductal Carcinoma in SituHereditary Breast Carcinoma+1 more
M.D. Anderson Cancer Center600 enrolled4 locationsNCT04169542
Recruiting
Phase 2

High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer

Estrogen Receptor-Positive Breast CarcinomaAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage 0 Breast Cancer AJCC v8+5 more
City of Hope Medical Center36 enrolled1 locationNCT06538389
Recruiting

The PREDICT Registry:

DCISDuctal Breast Carcinoma In SituStage 0 Breast Cancer
PreludeDx3,000 enrolled30 locationsNCT03448926
Recruiting
Phase 2

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

Urothelial CarcinomaBladder CancerNon-Muscle-Invasive Bladder Cancer (NMIBC)+8 more
Michael A. O'Donnell174 enrolled1 locationNCT07322263
Recruiting
Not Applicable

Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage I Breast Cancer AJCC v8+20 more
M.D. Anderson Cancer Center15 enrolled1 locationNCT02918474
Recruiting
Not Applicable

Endoscopic Nipple-Sparing Mastectomy Through a Single Axillary Incision in Breast Cancer

Breast CancerBreast Cancer - Ductal Carcinoma in Situ (DCIS)
Fondazione del Piemonte per l'Oncologia10 enrolled1 locationNCT07507890
Recruiting
Phase 2

Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST)

Breast CancerDuctal Carcinoma in SituEarly Stage Breast Cancer+1 more
UNC Lineberger Comprehensive Cancer Center90 enrolled1 locationNCT06902311